# Pharmacology and Pharmacometrics Core

> **NIH NIH P30** · JOHNS HOPKINS UNIVERSITY · 2022 · $164,293

## Abstract

ABSTRACT – JHU TRAC PHARMACOLOGY AND PHARMACOMETRICS CORE (PPC)
The Pharmacology and Pharmacometrics Core (PPC) will foster the creation, implementation, and conduct of
new tuberculosis (TB) therapeutics research, harnessing existing and new physical and human resources, in the
furtherance of: 1) Clinical and translational pharmacology-informed drug evaluation and development; and 2)
Education and development of New Investigators (NI) in this field. There is a need for new and better therapeutics
for the treatment of TB. Understanding pharmacokinetic-pharmacodynamic (PK/PD) relationships is key to
advancing drug development and being able to develop rational therapeutics and successful treatment for all by
determining the right drug at the right dose for the right patient. The PPC will provide added value to the JHU
TRAC by offering state-of-the-art analytical chemistry support for the development and use of drug assays
of biological samples, clinical and translational pharmacology support for design of pre -clinical and clinical
studies, and quantitative pharmacology support for analysis, interpretation, and integration of preclinical
and/or clinical data to support NI and established investigators studying novel aspects of TB treatment. The
PPC is led by Drs. Kelly Dooley (Director, Clinical Pharmacology) and Michelle Rudek (Co-Director, Analytical
and Clinical Pharmacology) at JHU, with senior leadership input by Dr. Eric Nuermberger (JHU, Translational
Pharmacology) and Dr. Joga Gobburu (Pharmacometrics) at the University of Maryland. This team has several
decades of combined experience in pre-clinical and clinical pharmacology. The specific aims of the PPC are to:
1) Provide consultative clinical and translational pharmacology support for JHU TRAC, and assist and mentor
investigators in the design and conduct of preclinical and clinical studies focused on TB therapeutics; 2) Provide
state-of-the-art, Good Laboratory Practice (GLP)-quality evaluations to quantify drugs (and metabolites) to treat
TB in biological samples; and 3) Provide PK and PK/PD data analysis and interpretation to support translational
and clinical projects involving TB drugs, and to support decision-making for safe and efficient drug development.
The PPC will synergize with the TRAC by providing support and training opportunities for NI/ESI recipients of
Developmental Awards involving studies with PK/PD components, and by participating in the weekly TRAC
Seminar Series, the TRAC-specific Writing Accountability Groups (WAGs) for NI/ESI, the TRAC K-Club and K2R
Club, the annual TB Scientific Meeting and TRAC Data Fair. The PPC investigators look forward to applying their
collective expertise to benefit TB clinical care by promoting innovative approaches to TB treatment and
accelerating experimental therapeutic agent development.

## Key facts

- **NIH application ID:** 10431024
- **Project number:** 1P30AI168436-01
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Kelly E. Dooley
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $164,293
- **Award type:** 1
- **Project period:** 2022-03-16 → 2027-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10431024

## Citation

> US National Institutes of Health, RePORTER application 10431024, Pharmacology and Pharmacometrics Core (1P30AI168436-01). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10431024. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*